Topic Listing for Exelixis

Able Ontents Accounting Tax Considerations
Accounting Treatment Ackground
Acknowledgement Acknowledgment Commencement Date
Aconic Rtemis Acquire Products Technologies Skills Opportunistically
Acquired In-process Research Development Acquisitions
Actions Requiring Majority Vote Shareholders Committee Actions Requiring Unanimous Vote Shareholders Committee
Adam-10 Patents Added Agreement Read Entirety Follows Special Consultants
Added Agreement Read Entirety Follows Special Consulting Inventions Added Agreement Read Entirety Follows Stylemargin-top6pxmargin-bottom0px Margin-left4 Text-indent4
Additional Capital Not Available Forced Delay Reduce Eliminate Additional Collaboration Targets
Additional Definitions Additional Effects Termination
Additional Purchased Assets Additional Representations
Additional Representations Warranties Exelixis Additional Requirements Except Extent Genentech Self-insures 127 Following
Address Advance Facilities Payments
Affiliates Aggregated Option Exercises Last End Values
Aggregated Stock Options 2004 Agreement
Agreement Each Pricing Shall Governed Construed Accordance Laws Agreement Sell Plant Trait Assets
Agreement Shall Construed Accordance Governed Respects Internal Laws Agreement Shall Governed Construed Accordance Laws State New
Agricultural Collaborations Agriculture
Agriculture Leveraging Capabilities Additional Revenue Opportunities Agrigenetics Eps Desire Amend Agreement Accordance 1410 Provide
Agrigenetics Eps Desire Amend Agreement Accordance 1410 Re-define Agrigenetics Representations Warranties Represents Warrants Eps Effective Date
Agrinomics Agritope
Ahresabschluss Aintaining Onfidential Nformation
Ale Urchased Ssets Icenses Alliance Managers
Alvatorische Lausel Ame Egistered Ffice Inancial Ear
Amended Restated 2000 Equity Incentive Plan Amended Restated Patent Security Agreement Mortgage
Amendment Amendment Continuation Prior Plan Transfer Funds Other Qualified
Amendment Lease Amendment Successors Assignment Counterparts
Amendment Termination Amendments
Amendments Loan Agreement Among Xelixis Ayer Orporation Ptera Llc
Amortization Intangible Assets Amortization Intangibles
Amount Terms Advances Anagement Epresentation
Anaging Irectors Ancellation Hares
Angiogenesis Annex
Annex Ii-1 Annex Ii1
Annex Iii1 Annex Iv10
Annex Iv13 Annex Iv14
Annex Iv15 Annex Iv17
Annex Iv3 Annex Iv4
Annex Iv5 Annex Iv8
Annex Vi3 Annex Viii6
Annual Development Plans Annual Meeting
Annual Meeting Attendance Annual Revenues Net Loss Down Cash Position Strong
Annual Worldwide Aggregate Net Sales Bms Affiliate Sublicensee Anti-takeover Provisions Charter Documents Delaware Law Make Acquisition
Application 409a Approval Artemis
Arbitrator Confidentiality Agreement Meaning Set Forth 146 126 Areas Expertise
Arks Artemis
Artemis Pharmaceuticals Asis Ayments Rom Lan
Asset Purchase License Agreement Assignment
Assignment Assumption Agreement Assignment Form
Assistance Questions Atification Election Ndependent Egistered Ublic Ccounting Irm
Attached Loan Agreement Hereby Deleted Entirety Replaced Hereto Attestation Report Independent Registered Public Accounting Firm
Audit Committee Authority
Authority Duties Available
Available Information Awards Granted 2008 2000 Equity Plan
Back-up Work Background
Backup Compounds Backup Programs
Balance Page Intentionally Left Blank Bankruptcy
Basis Consolidation Basis Presentation
Bayer Bayer Corporation
Bayer Cropscience Becatecarin
Beneficial Owner Shares Registered Name Broker Bank Beneficial Ownership Reporting Compliance
Between Bill Sale
Black-scholes Value Blackout Provisions Respect Designated Shares
Bms Independent Research Development Manufacture Commercialization Products Bms License Limitations Covenants Retained Rights
Board Committees Meetings Board Directors Executive Compensation
Board Directors Stockholders Exelixis Inc Boehringer Ingelheim
Boehringer Ingelheim International Gmbh Collaboration Bristol-myers Squibb
Bristol-myers Squibb Exelixis Enter Global Collaboration Bristol-myers Squibb Forward-looking Statement
Bristol-myers Squibb Forward-looking Statements Budget Allocation Deviations
Budgets Business Development
Business Highlights Business Update
Calculation Payment Profit Loss Share Cancer
Cancer Collaboration Cancer Collaboration Bristol-myers Squibb
Cancer Compounds Cash
Cash Compensation Cash Compensation Arrangements
Cash Compensation Non-employee Directors Cash Investments
Cash Requirements Cell Cycle Regulation
Cell Factory Assets Cell Growth
Cell Survival Certain Business Relationships
Certain Confidential Information Contained Document Marked Brackets Filed Certain Definitions
Certain Factors Affect Business Certain Factors Important Understanding Financial Condition Result Operations
Certain Factors Important Understanding Financial Condition Results Operations Certain Relationships Related Transactions
Certain Transactions Certification
Change Control Severance Benefit Plan Change Control Severance Plan
Change Vote After Submitting Proxy Changes Accounting
Charter Compensation Committee Check Applicable Box
Check Appropriate Box Below Form 8-k Filing Intended Chemistry Collaborations
Clarity Each Compound Shall Cease Collaboration Becomes Excluded Class Director Continuing Office Until 2006 Annual Meeting
Class Directors Continuing Office Until 2007 Annual Meeting Class Directors Continuing Office Until 2008 Annual Meeting
Class Directors Continuing Office Until 2009 Annual Meeting Class Directors Continuing Office Until 2010 Annual Meeting
Class Directors Continuing Office Until 2011 Annual Meeting Class Nominees Election Three-year Term Expiring 2008 Annual
Class Nominees Election Three-year Term Expiring 2009 Annual Class Nominees Election Three-year Term Expiring 2010 Annual
Class Nominees Election Three-year Term Expiring 2011 Annual Class Nominees Election Three-year Term Expiring 2012 Annual
Clinical Development Clinical Development Commercialization
Clinical Pipeline Clinical Preclinical Pipeline
Clinical Supply Clinical Testing Product Candidates Lengthy Costly Complex Uncertain
Clinical Testing Product Candidates Lengthy Costly Uncertain Process Clinical Trial Accruals
Clinical Trials Closing Delivery Payment
Co-branding Code Ethics
Collaboration Collaboration Agreement
Collaboration Arrangements Collaboration Cost-sharing
Collaboration Cost-sharing Expenses Collaboration Governance Committee Structure
Collaboration Guidelines Collaboration Targets
Collaborations Outside Scientists Subject Restriction Change Commercial Success Products Develop Depend Degree Market Acceptance
Commercialization Plans Commercialization Report
Commercialization Responsibilities Commitments
Committee Board Directors Committees
Common Stock Warrants Company-specific Factors
Compensation Compensation Arrangements
Compensation Committee Compensation Committee Interlocks Insider Participation
Compensation Committee Process Compensation Decisions
Compensation Directors Compensation Executive Officers
Compensation Information Named Executive Officers Compensation Information Non-employee Directors
Competing Programs Exclusivity Competition
Competitors Develop Products Technologies Make Obsolete Completion Acquisition Disposition Assets
Completion Shall Mean Following Events Particular Category Compound Composition
Compound Collaborations Compounds
Compounds Being Developed Internally Co-developed Partner Compounds Effective Date
Compounds Metabolic Cardiovascular Disorders Compounds Series
Comprehensive Income Comprehensive Income Loss
Comprehensive Loss Concentration Credit Risk
Conclusion Conclusion Collaboration Glaxosmithkline
Conclusion Six-year Collaboration Glaxosmithkline Conditions Disbursements
Conduct Research Conference Call Webcast
Confidentiality Confidentiality Information Disclosed Party Other Pursuant Agreement Shall
Conflicts Collaborators Jeopardize Outcome Collaboration Agreements Ability Commercialize Conflicts Collaborators Jeopardize Outcome Collaborative Agreements Ability Commercialize
Consent Independent Registered Public Accounting Firm Consolidated Balance Sheet Data
Construction Consulting Agreement
Consulting Agreements Contact
Contract Research Agreement Contributions Subsection 104
Controls Procedures Convention
Copies Shareholder Loans Core Representation Shall Mean Representations Warranties Set Forth
Corporate Agreements Resolution Promises Corporate Collaborations
Corporate Development Corporate Governance
Corporate Seal Costs Associated Exit Disposal Activities
Costs Backup Programs Covenants Each Party
Covenants Indemnifications Coverages Each Party Shall Maintain Own Cost Insurance
Covered Compounds Means Country-by-country Basis Licensed Compound Whose Creation Direct Financial Obligation Off-balance Sheet Arrangement
Critical Accounting Estimates Cross Border Transactions
Daiichi Sankyo Limited Data Report Xl880 Submitted Glaxosmithkline
Dated 2005 Debarment Other Sanctions
Decision Glaxosmithkline Not Exercise Development Option Xl647 Decision Glaxosmithkline Not Exercise Development Option Xl784
Decision-making Deerfield Credit Facility
Deerfield Facility Defense Party Claims
Definitions Definitions Financial Appendix
Definitions Interpretations Above Tables Departure Directors Principal Officers Election Appointment Compensatory
Depend Exclusive Licensee Helsinn Completion Xl119 Clinical Program Dependent Collaborations Major Companies Unable Achieve Milestones Develop
Deposit Account Description Comfort Letter
Description Exchange Program Description Premises
Development Development Cost Deferral
Development Costs Development Payments
Development Regulatory Milestones Development Royalty-bearing Products
Development Update Development Updates
Deviations German Gaap Difficulties Encounter Managing Growth Divert Resources Limit Ability
Director Compensation 2006 Director Compensation 2007
Director Compensation 2008 Director Compensation Table
Directors Directors Executive Officers Registrant
Disagreements Between Sei Regarding Development Product Candidates Xl647 Disciplined Management Financial Resources
Disclosure Research Inventions Patent Prosecution Discovery
Dispositions Dispute Resolution
Dissenters Rights Dissolution Transition Committee Shall Dissolve Date After Effective
Dividends Documents Incorporated Reference
Documents Provided Genentech Exelixis Following Opt-in Dog Boundaries Work
Dog Visit Policy Dog Visitation Policy
Dollars Shall Mean United States Dow Agrosciences
Drug Discovery Each Subsequent Contract
Early Termination Ebitda Artemis
Ecitals Econd Mendment
Ection Eneficial Wnership Eporting Ompliance Eemployment
Effect Stockholders Effect Termination
Effect Termination Expiration Effect Termination Survival
Effective Date Hsr Act Filing Effective Date Parties Agree Agreement 2007
Efinitions Egal Onstruction
Egenstand Des Nternehmens Egistered Apital
Ekanntmachungen Election Class Directors
Election Participate Elements Compensation
Eligible Employees Eligible Options
Emea Means European Medicines Agency Decentralized Body Union Employee Benefit Plans
Employee Stock Purchase Plan Employees
Employer Elect Option Below Complete Additional Provisions Addendum Employer Elect Option Below Complete Superseding Provisions Addendum
Employers Copy Employment Agreements
Employment Severance Change Control Agreements Enentech Xelixis Egotiation Ights
Eneral Rovisions Enforce Rights
Enforcement Enforcement Exelixis Sole Patents
Enforcement Joint Patents Enforcement Patent Rights
Entry Credit Facility Entry Material Definitive Agreement
Eport Udit Ommittee Eporting Bligations
Epresentations Arranties Equipment Line Credit
Equity Compensation Arrangements Equity Compensation Non-employee Directors
Equity Compensation Plan Information Equity Incentive Plan Amended Restated Combines Compensation
ErfÜgungen Über EschÄftsanteile Erm
Erm Ermination Ervices
Erwendung Des Ewinns EschÄftsfÜhrung Und Ertretung
Esearch Rogram Esellschafterausschuss
EsellschafterbeschlÜsse Esellschafterversammlungen
Esignation Rofit Hare Ield Roducts Esponsibilities
Estimates Estrictions Isposal Hares
Evelopment Evelopment Ommercialization Roducts
Event Licensee Committing Material Breach Terms Agreement Failing Events Default
Everability Exact Name Registrant Specified Charter
Exchange Ratios Excluded Assets
Exclusive Collaboration Discovery Pi3k Inhibitors Exclusive Licenses
Exclusivity Executed Date Above Written
Execution Copy Execution Special Power Attorney
Executive Compensation Executive Officer Promotions
Executive Officers Executive Officers Exelixis
Exel-6897 Patent Applications Exelixis
Exelixis Announces 2005 Financial Results Exelixis Announces 2006 Financial Results
Exelixis Announces 2007 Financial Results Business Update Exelixis Announces 2008 Financial Results
Exelixis Announces 2009 Financial Results Exelixis Announces Full 2008 Financial Results
Exelixis Announces Offering Common Stock Exelixis Announces Pricing Public Offering Common Stock
Exelixis Announces Proposed Public Offering Common Stock Exelixis Clinical Trials
Exelixis Corporate Acknowledgment Exelixis Development Expenses
Exelixis Exclusivity Obligations Exelixis Forward-looking Statement
Exelixis Forward-looking Statements Exelixis Fxr Program
Exelixis Inc Exelixis License Limitations Covenants
Exelixis License Limitations Covenants Retained Rights Exelixis Logo Registered Trademarks
Exelixis Logo Registered Trademarks Spectrum Selective Kinase Inhibitor Exelixis Marks
Exelixis Opt-out Rights Exelixis Option Rights
Exelixis Patents Exelixis Press Release
Exercise Bristol-myers Squibb Development Option Xl139 Exercise Genentech Development Option Xl518
Expect Quarterly Results Operations Fluctuate Fluctuation Cause Stock Expectations Dog Owners
Expenses Reimbursement Explanation Deviation Planned Development Regulatory Timelines
Explanation Safety Events Leading Label Changes Product Withdrawal Explanatory
Exposed Risks Associated Acquisitions Exposed Risks Related Foreign Currency Exchange Rates
Face Potential Product Liability Exposure Far Excess Limited Facilities
Facility Agreement Facility Management Reimbursement
Fair Value Financial Instruments Fair Value Measurements
Federal Income Tax Consequences Fees
Ffective Ate Fidelity Basic Plan Document
Filing Prosecution Maintenance Exelixis Prosecuted Patents Filing Prosecution Maintenance Sanofi-aventis Prosecuted Patents
Financial Outlook Financial Results
Financial Statements Financial Statements Exhibits
Financing Activities Find Out Results Voting Annual Meeting
Fixing Record Dates Fold Detach Here
Following Summary 2000 Equity Plan Qualified Entirety Reference Following Summary 2000 Purchase Plan Qualified Entirety Reference
Following Summary Espp Qualified Entirety Reference Amended Board Foreign Currency Translation
Form 10-k Form 10-q
Form Designated Shares Form Development Report
Form Opinion Form Opinion Mcdonnell Boehnen Hulbert Berghoff Llp
Form Special Power Attorney Form Target Status List
Form Warrant Former Name Address Changed Since Last Report
Forward Looking Statement Forward Looking Statements
Forward-looking Statement Forward-looking Statements
Frequency Reporting Fte Payment Schedule
Fte Payments Further Actions Each Party Agrees Execute Acknowledge Deliver
Further Assurances Access Books Records Future Sales Common Stock Depress Price
Genentech Genentech Collaboration
Genentech Excluded Genentech Right Negotiate
Genentech Take Strategic Leadership Cancer Exelixis Inflammation Tissue General
General Administrative Expenses General Committee Membership Procedures
General Provisions Relating Enforcement Patents Generally Rights Represented Warrant Exercised Whole Part Time
Genomica Genomica Corporation
Genoptera Genoptera Collaboration
Gewinn- Und Verlustrechnung Für 2006 Glaxosmithkline
Glaxosmithkline Collaboration Glaxosmithkline Loan Repayment Obligations
Global Credit Financial Market Conditions Negatively Impact Value Global Development Plans
Global License Agreement Collaboration Sanofi-aventis Goodwill Impairment
Goodwill Intangible Impairment Goodwill Other Acquired Intangibles
Governing Law Consent Jurisdiction Service Process Governing Law Plan Accompanying Adoption Agreement Shall Construed
Governing Law Trust Agreement Shall Construed Administered Enforced Government Regulation
Grant Security Grants Plan-based Awards
Grants Plan-based Awards 2007 Grants Plan-based Awards 2008
Greement Gsks Appointment Attorney-in-fact
Guaranty Hareholder Esolutions
Hareholder Rotective Rovisions Hareholders Eeting
Hareholders Eetings Hareholders Greement
Hareholders Ommittee Hazardous Chemicals Radioactive Biological Materials Business Claims Relating
Headings Plan Included Convenience Reference Only Shall Not Headquarters Facilities Located Near Known Earthquake Fault Zones
Headquarters Located Near Known Earthquake Fault Zones Occurrence Held 2009
Helsinn Discontinue Becatecarin Trial Program Helsinn Healthcare
Herefore Agreed Between Eps Agrigenetics Follows Icense Greement Herefore Exelixis Wyeth Agree Follows Efinitions
Herefore Parties Agree Follows Ifth Mendment Greement Highlights
Highlights Recent Developments Hird Arty Laims Ndemnification
Hiring History Net Losses Expect Continue Incur Not Achieve
Holders Householding Proxy Materials
Icenses Icenses Ther Ights
Ight Nterpret Lan Mendment Ermination Ignature Age Ssignment Ssumption Greement
Illustrative Example Profit Share Calculation Ime Orm Everance Ayments
Imitations Enefits Immediate Release
Implementation Exchange Program Important Notice Concerning Rights Exelixis Inc 401 Plan
In-service Withdrawal Age 595 Deferral Source In-service Withdrawals
Inancial Eporting Inancial Erms
Inc Effective 2002 Incentive Stock Options
Income Tax Benefit Income Tax Provision
Income Taxes Increase Authorized Number Shares 1850000
Ind Submission Indebtedness Management
Indemnification Indemnification Agreements
Indemnification Directors Executive Officers Other Employees Agents Indemnification Limitation Liability
Indemnities Independent Auditors Fees
Index Index Consolidated Financial Statements
Index Exhibits Individuals Classified Interns Project Employees Employer Means Employed
Industry-wide Factors Informatics Code Means Generated Either Party Agreement 159
Information Exchange Identified Targets Information Included Transfer Manufacturing Technology
Initial Development Plans Initial Opportunity Opt-in
Injunctive Relief Insurance Agrigenetics
Insurance Eps Intangible Assets
Integrated Drug Research Discovery Development Capabilities Integrated Research Discovery Development Capabilities
Intellectual Property Introduction
Investing Activities Investment Contributions
Investment Review Committ Inziehung Von EschÄftsanteilen
Irma Itz Und EschÄftsjahr Irst Mendment
Iscellaneous Isposal Hares
Ispute Esolution Respect Inancial Tatements Ist Ransaction Greements
Itnesseth ItverÄußerungsrecht Orkaufsrecht Ndienungspflicht
Joint Commercialization Committee Joint Development Regulatory Committee
Joint Executive Committee Joint Management Team
Joint Press Release Joint Product Patents
Joint Project Team Joint Research Committee Discovery Working Group
Joint Research Development Committee Joint Steering Committee
Key Personnel Means 163 List Key Responsibilities
Lack Capability Manufacture Compounds Clinical Trials Rely Parties Laims Nquiries Ppeals
Landlord Tenant Desire Subject Terms Conditions Set Forth Landlords Tenants Property
Laws Regulations Reduce Ability Sell Genetically Engineered Products Lead Discovery
Lead Nomination Lead Optimization
Lead Programs Lease Agreement
Leased Real Property Leases
Lection Lass Irectors Legal Relations Between Seller Artemis Surviving Closing Date
Letter Agreement Letter Credit
Letter Credit Restricted Cash Leverage Strategic Collaborations
Liability Insurance Landlord Tenant Shall Each Procure Maintain License Agreement
License Diagnostic Product License Grants
License Reversion Compound Product Licensee Shall Marks Labels Packaging Promotional Marketing Materials
Licenses Exelixis Licenses Genentech
Licenses Payments Termination Licenses Related Rights
Licenses Sanofi-aventis Exelixis Retained Rights Co-branding Licensing Agreements
Licensor Hereby Warrants Licensee Owner Marks Retains Rights Ligibility Enefits
Limitations Liability Limited Sources Revenues
Liquidity List
List Initial Exelixis Clinical Trials List Persons Sign Lock-up Agreements Form Annex Ii-2
List Phase Clinical Trials Subject Litigation Third-party Claims Intellectual Property Infringement Require Spend
Loan Payment Glaxosmithkline Loan Security Agreement
Loans Officers Long Ight Mption Rag
Long-lived Assets Loss Key Personnel Inability Attract Retain Additional Impair
Loss Key Personnel Inability Retain Necessary Attract Additional Lxr Collaboration
Management Financial Resources Managements Report Internal Control Over Financial Reporting
Managing Directors Prokurists Manufacturing Activities
Manufacturing Exelixis Manufacturing Generally
Manufacturing Raw Materials Manufacturing Update Clinical Commercial
Marked Signed Returned Proxy Card Market Registrants Common Equity Related Stockholder Matters Issuer
Material Defects Products Services Material Insurance Agreements
Material Permits Material Transfer
Material Transmittal Form Materials Necessary Manufacture Some Compounds Currently Development Not
Meaning Set Forth 193 Meetings
Mek Collaboration Membership
Mendment Greement Mendment Tock Urchase Greement
Metabolic Disorders Cardiovascular Compounds Metabolic Disorders Cardiovascular Disease
Metabolic Program Might Material Way Additional Representations
Migration Milestone Payment Restrictions
Milestone Payments Milestone Payments Exelixis
Milestone Royalty Payments Milestones Payable Achievement Respect Royalty-bearing Product Such Milestone
Minimum Minimum Purchase Obligation
Minutes Meetings Minutes Reports
Miscellaneous Mitigation Each Parties Hereto Shall Take Commercially Reasonable
Molecule Oncology Compound Mount Enefits
Mplied Mployment Ontract Mutual Covenants
Name Person Filing Proxy Statement Other Registrant Name Registrant Specified Charter
Named Executive Officer Compensation Named Fiduciary Administrator Purposes Erisa 402 Powers Responsibilities
Names Addresses Representative Nasdaq National Market Index Biotech
Ndemnification Ndex Nnexes
Net Loss Net Loss 2008 Was 413 039 Per Share
Net Loss Per Share New Accounting Pronouncements
New Collaboration Focuses Novel Compound Targeting Mek- New Plan Benefits
Nnual Inancial Tatements Nominating Corporate Governance Committee
Non Binding English Translation Non-compete
Non-competition Non-employee Director Compensation
Non-employee Directors Stock Option Plan Non-exclusive Know-how
Non-gaap Financial Information Non-payment Expenses
Non-relevant Targets Respect Each Licensed Product Noncontrolling Interest Symphony Evolution Inc
Nondisclosure Confidential Information Nonstatutory Stock Options
Not Able Manufacture Product Candidates Commercial Quantities Prevent Not Check Smaller Reporting
Not Realize Expected Benefits Initiatives Control Costs Notes Consolidated Financial Statements
Notice Blackout Period Notices
Notices Given Agreement Shall Writing Addressed Parties Following Notices Record Date Time
Novel Cancer Programs Nsurance
Ntellectual Roperty Ntroduction
Number 0-30235 Nventions
Objectives Compensation Program Off-balance Sheet Arrangements
Officers Offices
Ommercialization Ompensation
Ompensation Ommittee Eport Ompensation Ommittee Nterlocks Nsider Articipation
Ompete Ndertakings Oncology Collaboration
Onfidentiality Onsideration Elated Atters
Onstruction Ontract Esearch Greement
Ooley Odward Llp Ooperation Ndertakings
Operating Activities Operations
Opt-in Right Option Co-promote
Option Develop Exelixis Compound Exercised Genentech Option Exercises
Option Exercises 2006 Option Grants Last
Oral Presentations Organization
Orm 10-k Otarial Eed
Other Collaborations Other Events
Other Income Expense Net Other Joint Patents
Other Matters Other Matters Voted Annual Meeting
Other Regulatory Matters Other Securities Corporation
Other Targets Other Terms Conditions Replacement Stock Options
Otifications Ounterparts
Ouseholding Roxy Aterials Out-licensed Compounds
Outlook Outstanding Equity Awards Year-end
Ovenants Ompany Overning Ttorney Ees
Overview Overview Accounting
Overview Guidelines Independence Owned Corporation
Ownership Ownership Research Inventions
Packaging Marketing Materials Packaging Promotional Materials
Part Part Other Information
Partially Exclusive License Participant Loans
Participants Accounts Participation
Participation Notice Parties Rely Not Perform Contractually Required Expected Able
Party Claims Related Profit Share Products Party Infringement
Party Rights Party Royalties Products Royalty Territory Royalty-bearing
Patent Assignment Agreement Patent Prosecution Maintenance
Patent Prosecution Maintenance Abandonment Patent Prosecution Maintenance Enforcement
Patent Security Agreement Mortgage Patents
Patents Trademarks Equitable Relief Paying Proxy Solicitation
Payment Additional Purchased Assets Payment Terms
Pdl Biopharma Pdl Biopharma Inc
Pdx Facility License Agreement Pending Disputes
Pending Patent Applications Pension Plan Similar Commitment
Perating Rinciples Rocesses Perform Tech Transfer Drug Product Process Analytical Methods
Performance Liability Performance Measurement Comparison
Permitted Liens Persons Dealing Trustee Person Shall Bound See Application
Pharmaceutical Collaborations Phase Clinical Trial Program
Phase Trial Xl784 Did Not Meet Primary Endpoint Phase Updates
Pi3k Inhibitors Pipeline
Pipeline Update Plan
Plan Administration Plan Name Exelixis Inc 401
Planned Development Regulatory Timelines Policies Procedures Respect Related Party Transactions
Portfolio Potential Modification Exchange Program Terms Comply Governmental Requirements
Potential Payments Termination Change Control Potential Payments Termination Change-in-control
Power Attorney Ppropriation Rofits
Pproval Mendment Estatement Xelixis 2000 Quity Ncentive Lan Pre-approval Services
Pre-commencement Communications Pursuant Rule 13e-4 Exchange Act Cfr Pre-opt-in Studies
Preamble Preclinical Development
Preclinical Pipeline Preliminary Purchase Price Adjustment
Prerequisites Dog Project Pricing Agreement
Principal Accountant Fees Services Principles Calculation
Principles Reporting Priority Documents
Pro Forma Results Processes Procedures Determining Director Compensation
Product Candidates Subject Lengthy Uncertain Regulatory Process Not Product Supply
Profit Share Profit-share Territory Program Option
Properties Property Equipment
Proprietary Rights Prosecution
Prosecution After Bms Exercise Co-development Option Prosecution Enforcement Partially Exclusive Patents
Protein Design Labs Provisional Collaboration Programs Exercise Bms Co-development Option
Prudent Actions Plan Fiduciaries Ption Ights
Publication Updates Publications
Purchase Option Agreement Purchased Assigned Agreements
Purchased Facility Purchased In-process Research Development
Purchased Know-how Purchased Promoters Shall Mean Set Forth Schedule Without
Purchasers Warranties Purpose
Quality Responsibilities Relating Development Candidates Quality Responsibilities Relating Licensed Compounds
Quantitative Qualitative Disclosures Market Risk Quarterly Financial Data
Quity Ompensation Lan Nformation Quorum Voting
Rademark Icense Greement Ransition Committee Shall Meaning Set Forth
Ratification Selection Independent Auditors Ratification Selection Independent Registered Public Accounting Firm
Reamble Reasons Amend Restate 2000 Equity Plan
Receive Information Plan Benefits Receiving Materials
Recent Accounting Pronouncement Recent Accounting Pronouncements
Recent Developments Recitals
Reclassification Reconciliation Gaap Expenses Non-gaap
Reconciliation Gaap Net Loss Non-gaap Records
References Collaboration Referred Echnology Ccess Xelixis
Registrants Telephone Number Including Area Code Registration Rights Agreement
Regulation Disclosure Regulatory Cmc Responsibilities
Regulatory Responsibility Regulatory Updates
Reimbursement Expenses Related
Related Party Transactions Relevant Party Collaborations
Remainder Page Intentionally Left Blank Remedies
Renessen Repayment
Report Audit Committee Report Board Time Whenever Shall Called Authority
Report Compensation Committee Report Independent Registered Public Accounting Firm
Report Independent Registered Public Accounting Firm Consolidated Financial Report Independent Registered Public Accounting Firm Internal Control
Reporting Representations Warranties
Representations Warranties Covenants Representations Warranties Covenants Exelixis
Research Research Development
Research Development Activities Existing Compound Prior Opt-in Research Development Agreement
Research Development Commercialization Reverted Compounds Exelixis Research Development Committee
Research Development Expenses Research Discovery
Research Plan Research Plan Success Criteria Additional Listed Nhrs
Reserved Shares Responsibility Reporting
Ress Elease Restricted Encumbered Titles Assets
Restructuring Charge Restructuring Charges
Results Operations Financial Condition Retirement Plan
Revenue Recognition Revenues
Revenues Significant Collaborators Reverted Compound Patents
Revoke Proxy Right Benefits
Right Licenses Covenants Rights Claims Shareholder Loans
Rights Technology Risk Factors
Risks Related Commercialization Products Risks Related Development Product Candidates
Risks Related Employees Growth Location Risks Related Environmental Product Liability
Risks Related Regulatory Approval Product Candidates Role Compensation Committee Executive Officers Decisions
Roposal Royalties
Royalty Adjustments Royalty Payments
Royalty Payments Exelixis Royalty Payments Other Territory
Royalty Report Calendar Rticles Ssociation
Rules Regulations Salary Information Named Executive Officers
Sale Equity Shares Sale Interest Artemis Pharmaceuticals Gmbh
Sale Plant Trait Assets Sale Plant Trait Business
Sales Product Against Sankyo
Sanofi-aventis Sanofi-aventis License Limitations Covenants
Schedule Schedule Cell Factory Assets
Schedule Computers Schedule Excluded Patents
Schedule Excluded Portfolios Schedule Non-exclusive Know-how
Schedule Non-exclusive Patents Schedule Partially Exclusive Patents
Schedule Purchased Know-how Schedule Purchased Operative Assets
Schedule Purchased Patents Schedule Purchased Promoters
Schedule Sellable Agreements Screening Programs
Securities Exchange Securities Exchange Act 1934
Securities Registered Pursuant Act Security Breaches Disrupt Operations Harm Operating Results
Security Ownership Certain Beneficial Owners Management Related Stockholder Selectively Develop Therapeutic Products First-in-class Best-in-class Potential
Selectivity Panel Means Protein Kinases Selectivity Panel Upstate
Sellable Assets Series 213323 209624 212215 222544
Series 218833 Serious Adverse Cardiovascular Events Observed Phase Clinical Trial
Serious Adverse Cardiovascular Events Observed Xl999 Clinical Program Serious Adverse Cardiovascular Events Observed Xl999 Program Result
Service Shall Amended State Entirety Contract
Shall Amended State Entirety Transition Consultation Shall Mean Affiliates
Shareholders Agreement Attached Executed Version Being Filed Exelixis Shares Stock
Signature Signature Page Asset Purchase License Agreement
Signature Page Bill Sale Signature Page Contract Research Agreement
Signature Page Follows Signature Page Lease Agreement
Signature Page Patent Assignment Agreement Signature Page Pdx Facility License Agreement
Signature Page Pricing Agreement Dated 2005 Signatures
Signatures Follow Next Page Signatures Next Page
Smithklinebeecham Corporation Glaxosmithkline Social Issues Limit Public Acceptance Genetically Engineered Products
Some Existing Stockholders Exert Control Over Interests Conflict Soon Practicable After Effective Date Seller Shall Transfer
Sources Uses Cash South San Francisco 94083
Special Committee Adjustment Spectrum Selective Kinase Inhibitor Trademark Exelixis Inc
Ssignment Ease Ssignment Ssumption Ease Greement
Ssumed Iabilities Xcluded Ssumption Bligations
Statutory Warranty Deed Stock Bonus
Stock Bonuses Restricted Awards Stock Option Grants 2004
Stock Option Grants Exercises Stock Option Plans
Stock Option Valuation Stock Price Extremely Volatile
Stock Purchase Plan Stock Repurchase Agreements
Stock-based Compensation Stockholder Communications Board Directors
Stockholder Proposals Due Next Annual Meeting Stockholder Record Shares Registered Name
Stockholders Exelixis Inc Stockholders Meetings
Strategy Strategy Update
Studies Subject Damages Resulting Claims Employees Independent Contractors Wrongfully
Sublicense Certain Party Intellectual Property Sublicensing
Subsequent Event Subsequent Event Glaxosmithkline Collaboration
Subsequent Events Subsequent Opportunities Genentech Exercise Opt-in Right
Subsidiaries Exelixis Subsidiaries Exelixis Inc
Such Other Responsibilities Assigned Jdc Pursuant Agreement Agreed Such Other Responsibilities Assigned Jec Pursuant Agreement Agreed
Such Other Responsibilities Assigned Jrdc Pursuant Agreement Agreed Summary Compensation
Summary Compensation Table Supply Product Existing Phase Clinical Trial
Survival Survival Effect Termination
Symphony Evolution Symphony Evolution Inc
Table Contents Tammkapital
Target Identification Validation Target Multiple Pathways
Target Potency Threshold Target Specificity Threshold
Target Specificity Threshold Means Tatement Erisa Ights
Tatement Olicy Tax Cooperation Allocation Certain Taxes
Technology License Agreement Temporary Suspension Trading Registrants Employee Benefit Plans
Tenants Notice Address Tenure Duties Officers
Term Termination Termination
Termination Exelixis Breach Termination Material Breach
Termination Material Breach Patent Challenge Termination Material Definitive Agreement
Terms Co-promotion Agreement Terms Profit Share Products Financial Including Relevant Cost
Ther Atters Ther Lan Nformation
Time Annual Worldwide Aggregate Net Sales Products Reach Time Delivery
Title Class Total Other Income
Total Other Income Expense Total Other Income Expense Net
Transfer Assumed Contracts Transfer Manufacturing Right
Transfer Manufacturing Technology Transfers
Transgenic Animals Transition Consultation
Translational Research Trategic Oals
True-up Capital Expenditures True-up Facilities Expenses
Trustees Copy Uccessors Ssigns
Unable Adequately Protect Intellectual Property Parties Able Technology Unable Establish Sales Marketing Capabilities Enter Agreements Parties
Unable Obtain Adequate Coverage Reimbursement Third-party Payors Products Undersigned Acknowledges Been Advised Obtain Tax Financial Advice
Undersigned Hereby Certifies Warrant Being Sold Assigned Transferred Understand Agree Completely Terms Set Forth Exelixis Inc
Unding Bligation Unregistered Sales Equity Securities
Unwanted Target Update Financial Outlook
Update Notice Blackout Period Upfront Payment License Payments
Upstate Panel Meaning Described 188 Urpose Ompany
Vacancies Validation
Vesting Replacement Stock Options Void After 2010
Void After 2011 Void After 2014
Volume Submitter Defined Contribution Plan Vote
Vote Annual Meeting Votes
Votes Counted Votes Needed Approve Each Proposal
Warrant Purchase Agreement Warrants
Way Example Calendar Amount Net Sales Product Exelixis What Deadline Submitting Stockholder Proposals 2007 Annual Meeting
What Deadline Submitting Stockholder Proposals 2008 Annual Meeting What Deadline Submitting Stockholder Proposals 2009 Annual Meeting
What Deadline Submitting Stockholder Proposals 2010 Annual Meeting What Mean Receive Proxy Card
What Proxy Materials Available Internet What Quorum Requirement
What Return Proxy Card Not Make Specific Choices What Voting
Whereas Willfully Encourages Solicits Then Current Employees Leave Employ
Witnesseth Wyeth
Wyeth Pharmaceuticals X-ceptor
X-ceptor Therapeutics Xecution
Xecution Opy Xecutive Fficers
Xelixis Xelixis Ristol Yers Quibb Ompany
Xercise Arrant Xhibit
Xhibit 1024 Xhibit 1029
Xhibit 104 Xhibit 105
Xhibit 1054 Xhibit 1061
Xhibit 1064 Xl119 Becatecarin
Xl147 Xl147 Patent Applications
Xl147 Xl765 Xl147 Xl765 Exel-6897
Xl184 Update Xl281 Phase Inhibitor Raf Kinase
Xl413 Update Xl647 Update
Xl765 Exel-6897 Xl765 Exel-6897 Patent Applications
Xl765 Launch Broad Collaboration Discovery Pi3k Inhibitors Xl999 Update
Yale Patents Zustimmungserklärung
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki